Novartis Gets First-Mover Advantage With FDA Approval Of Cosentyx For Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Secukinumab gets to market before competing IL-17 inhibitors from Lilly and AstraZeneca/Amgen are even filed for approval. Wall Street is expecting blockbuster sales for psoriasis agents that can improve upon the performance of TNF inhibitors.